Combined analysis of inherited polymorphisms in arylamine N- acetyltransferase 2, glutathione S-transferases M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk

Cancer Research

Volumn 56, Issue 17, 1996, Pages 3915-3925

  Brockmöller, Jürgen ^a   Cascorbi, Ingolf ^a   Kerb, Reinhold ^a   Roots, Ivar ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; CYTOCHROME P450 ISOENZYME; EPOXIDE HYDROLASE; GLUTATHIONE TRANSFERASE;

ACETYLATION; ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; GENETIC POLYMORPHISM; HUMAN; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; SMOKING;

AGED; ALLELES; ARYLAMINE N-ACETYLTRANSFERASE; BASE SEQUENCE; CYTOCHROME P-450 ENZYME SYSTEM; EPOXIDE HYDROLASES; FEMALE; GLUTATHIONE TRANSFERASE; HUMANS; ISOENZYMES; MALE; MICROSOMES; MIDDLE AGED; MOLECULAR SEQUENCE DATA; POLYMORPHISM, GENETIC; RISK FACTORS; URINARY BLADDER NEOPLASMS;

EID: 0029815779     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (83)

1. Ames, B. N., Durston, W. E , Yamasaki, E., and Lee, F D Carcinogens are mutagens: a simple test system combining liver homogenates for activation and bacteria for detection. Proc. Natl Acad. Sci. USA, 70: 2281-2285, 1973.
2. Miller, E C. Some current perspectives on chemical carcinogenesis in humans and experimental animals. Cancer Res., 38: 1479-1496, 1978.
3. Caporaso, N., Landi, M. T., and Vineis, P. Relevance of metabolic polymorphisms to human carcinogenesis: evaluation of epidemiologic evidence. Pharmacogenetics, 1: 4-19, 1991
4. Idle, J. R., Armstrong, M., Boddy, A. V., Boustead, C., Cholerton, S., Cooper, J., Daly, A. K , Ellis, J., Gregory, W., Hadidi, H., Höfer, C., Holt, J., Leathart, J., McCracken, N , Monkman, S. C., Painter, J E , Taber, H., Walker, D., and Yule, M. The pharmacogenetics of chemical carcinogenesis. Pharmacogenetics, 2: 246-258, 1992.
5. Roots, I., Drakoulis, N., and Brockmöller, J Polymorphic enzymes and cancer risk: concepts, methodology and data review. In: W. Kalow (ed.), Pharmacogenetics of Drug Metabolism, pp. 815-841. New York: Pergamon Press, 1992.
6. Blum, M., Grant, D. M., McBride, W., Heirn, M., and Meyer, U A Human arylamine N-acetyltransferase genes isolation, chromosomal localization, and functional expression. DNA Cell Biol., 9: 193-203, 1990
7. Degushi, T., Mashimo, M., and Suzuki, T. Correlation between acetylator phenotypes and genotypes of polymorphic arylamine N-acetyltransferase in human liver. J. Biol. Chem., 265: 12757-12760, 1990.
8. Vatsis, K. P., Weber, W W., Bell, D. A., Dupret, J-M., Evans, D. A. P., Grant, D. M., Hein, D. W., Lin, H J , Meyer, U A., Relling, M. V., Sim, E., Suzuki, T , and Yamazoe, Y. Nomenclature of N-acetyltransferases. Pharmacogenetics, 5: 1-17, 1995.
9. Cascorbi, I., Drakoulis, N , Brockmöller, J., Maurer, A , Sperling, K., and Roots, I. Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals, correlation with phenotypic activity. Am. J. Hum. Genet., 57, 581-592, 1995.
10. Seidegård, J., Vorachek, W. R., Pero, R W., and Pearson, W. R. Hereditary differences in the expression of the human glutathione transferase active on trans-stilbene oxide are due to a gene deletion Proc. Natl Acad. Sci. USA, 85: 7293-7297, 1988.
11. Mannervik, B , Awasthi, Y. C., Board, P. G., Hayes, J. D., Di Ilio, C , Ketterer, B., Listowsky, I., Morgenstern, R , Muramatsu, M., Pearson, W. R , Pickett, C. B., Sato, K., Widersten, M., and Wolf, C R. Nomenclature for human glutathione transferases. Biochem J., 282: 305-308, 1992.
12. Thier, R , Taylor, J. B., Pemble, S. E. Humphreys, W. G., Persmark, M., Ketterer, B., and Guengerich, F. P. Expression of mammalian glutathione S-transferase 5-5 in Salmonella typhimurium TA1535 leads to base-pair mutations upon exposure to dihalomethanes. Proc. Natl Acad. Sci USA, 90: 8576-8580, 1993
13. Pemble, S., Schroeder, K. R., Spencer, S. R., Meyer, D. J., Hallier, E., Bolt, H. M., Ketterer, B., and Taylor, J. B. Human glutathione S-transferase θ (GSTT1). cDNA cloning and the characterization of a genetic polymorphism. Biochem. J , 300: 271-276, 1994
14. Gonzalez, F. J., Skoda, R. C., Kimura, S., Umeno, M., Zanger, U., Nebert, D. W , Gelborn, H. V., Hardwick, J. P., and Meyer, U. A. Characterization of the common genetic defect m humans deficient in debrisoquine metabolism. Nature (Lond.), 331: 442-446, 1988
15. Kagimoto, M., Heim, M., Kagimoto, K., Zeugin, T., and Meyer, U A Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine: study of the functional significance of individual mutations by expression of chimeric genes J. Biol Chem , 265: 17209-17214, 1990.
16. Meyer, U. A., and Gonzalez, F. J. Molecular genetics of the debrisoquine-sparteine polymorphism. Clin. Pharmacol. Ther., 50: 233-238, 1991.
17. De Morais, S. M. F , Wilkinson, G. R., Blaisdell, J., Nakamura, K., Meyer, U. A , and Goldstein, J. A. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol. Chem., 269, 15419-15422, 1994
18. Gaedigk, A., Spielberg, S. P., and Grant, D M Characterization of the microsomal epoxide hydrolase gene in patients with anticonvulsant adverse drug reactions. Pharmacogenetics, 4: 142-153, 1994.
19. Hassett, C., Aicher L , Sidhu J S., and Omiecinski C. J. Human microsomal epoxide hydrolase: genetic polymorphism and functional expression in vitro of amino acid variants Hum. Mol. Genet., 3: 421-428, 1994.
20. Kawajiri, K., Nakachi, K., Imai, K., Watanabe, J., and Hayashi, S-I The CYPIA1 gene and cancer susceptibility. Crit. Rev. Oncol Hematol., 14: 77-87, 1993.
21. Hayashi, S. I , Watanabe, J., and Kawajiri, K. Genetic polymorphisms in the 5′-flanking region change translational regulation of the human cytochrome P450IIE1 gene. J. Biochem., 110, 559-565, 1991
22. Weber, W. W., and Hein, D. W. N-acetylation pharmacogenetics Pharmacol. Rev., 37: 25-79, 1985.
23. Evans, D. A P N-acetyltransferase. In: W Kalow (ed.), Pharmacogenetics of Drug Metabolism, pp. 95-178 New York: Pergamon Press, 1992
24. Idle, J. R. Is environmental carcinogenesis modulated by host polymorphism? Mutat. Res., 247 259-266, 1991
25. Seidegård, J , Pero, R. W., Markowitz, M M , Roush, G., Miller, D G., and Beattie, E. J. Isoenzyme(s) of glutathione transferase (class μ) as a marker for the susceptibility to lung cancer, a follow up study. Carcinogenesis (Lond.), 11: 33-36, 1990
26. Bell, D. A., Taylor, J. A., Paulson, D F , Robenson, C N , Mohler, J L . and Lucier, G W. Genetic risk and carcinogen exposure: a common inherited defect of the carcinogen-metabolism gene glutathione S-transferase M1 (GSTM1) mat increases susceptibility to bladder cancer J. Natl Cancer Inst., 85: 1159-1164, 1993.
27. Lafuente, A , Pujol, F., Carretero, P., Perez Villa, J , and Cuchi, A. Human glutathione S-transferase Mu (GSTMU) deficiency as a marker for the susceptibility to bladder and larynx cancer among smokers Cancer Lett., 68: 49-54, 1993.
28. Daly, A. K., Thomas, D. J , Cooper, J., Pearson, W. R., Neal, D. E , and Idle, J R. Homozygous deletion of gene for glutathione S-transferase M1 in bladder cancer. Br. Med. J., 307: 481-482, 1993.
29. Brockmöller, J , Kerb, R , Drakoulis, N., Staffeldt, B., and Roots, I. Glutathione S-transferase M1 and its variants A and B as host factors of bladder cancer susceptibility: a case-control study. Cancer Res., 54: 4103-4111, 1994.
30. Crespi, C. L., Penman, B W., Gelboin, H V., and Gonzalez, F. J A tobacco smoke-derived nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, is activated by multiple human cytochrome P450s including the polymorphic human cytochrome P450 2D6. Carcinogenesis (Lond.), 12: 1197-1201, 1991.
31. Carmella, S. G., Akerbar, S., and Hecht, S S. Metabolism of the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in smoker's urine. Cancer Res., 55: 721-724, 1993.
32. Ayesh, R , Idle, J. R , Ritchie, J C., Crothers, M. J., and Hetzel, M. R. Metabolic oxidation phenotypes as markers for susceptibility to lung cancer. Nature (Lond.), 312: 169-171, 1984.
33. Cartwright R. A., Philip, P A., Rogers, H. J., and Glashan, R. W Genetically determined debrisoquine oxidation capacity in bladder cancer. Carcinogenesis (Lond), 5: 1191-1192, 1984.
34. Kaisary, A., Smith, P , Jacqz, E., McAllister, C. B., Wilkinson, G. R., Ray, W. A , and Branch, R. A. Genetic predisposition to bladder cancer: ability to hydroxylate debrisoquine and mephenytoin as risk factors. Cancer Res., 47: 5488-5492, 1987.
35. Benitez, J., Ladero, J. M., Fernandez-Gundin, M. J., Llerena, A., Cobaleda, J., Martinez, C., Munoz, J. J., Vargas, E., Prados, J., Gonzalez-Rozas, F., Rodriguez-Molina, J , and Uson, A. C Polymorphic oxidation of debrisoquine in bladder cancer Ann Med., 22: 157-160, 1990.
36. Roots, I., Drakoulis, N , Brockmöller, J., Janicke, I., Cuprunov, M., and Ritter, J. Hydroxylation and acetylation phenotypes as genetic risk factors in certain malignancies In: R. Kato, R. W Estabrook, and M N Cayen (eds.), Xenobiotic Metabolism and Disposition. London: Taylor & Francis, 499-506, 1989.
37. Romkes-Sparks, M , Mnuskin, A , Chern, H-D., Persad, R., Fleming, C., Sibley, S. N. A., Smith, P., Wilkinson, G. R , and Branch, R. A. Correlation of polymorphic expression of CYP2D6 mRNA in bladder mucosa and tumor tissue to in vivo debrisoquine hydroxylase activity. Carcinogenesis (Lond.), 15: 1955-1961, 1994
38. Pink, J. C., Messing, E. M., Reznikoff, C. A., Bryan, G. T. and Swaminathan, S. Correlation between N-acetyltransferase activities in uroepithelia and in vivo acetylator phenotype. Drug Metab. Dispos., 20: 559-565, 1992
39. Conney, A. H. Induction of microsomal enzymes by foreign chemicals and carcinogenesis by polycyclic aromatic hydrocarbons Cancer Res., 42: 4857-4917, 1982.
40. Guengerich, F P., Kim, D-H., and Iwasaki, M. Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects Chem Res. Toxicol, 4: 168-179, 1991
41. Drakoulis, N., Cascorbi, I., Brockmöller, J., Gross, C. R., and Roots, I. Polymorphisms in the human CYP1A1 gene as susceptibility factors for lung cancer, exon-7 mutation (4889 A to G), and a T to C mutation in the 3′-flanking region. Clin Invest., 72: 240-248, 1994.
42. Persson, I., Johansson, I , Bergling, H , Dahl, M-L., Seidegård, J , Rylander, R , Rannug, A , Hogverg, J., and Ingelman Sundberg, M. Genetic polymorphism of cytochrome P4502E1 in a Swedish population. FEBS Lett., 319: 207-211, 1993
43. Kantor, A F., Hartge, P., and Hoover, R. N. Familial and environmental interactions in bladder cancer risk. Int. J. Cancer, 35: 703-706, 1985.
44. Nakachi, K., Imai, K , Hayashi, S-I., and Kawajiri, K Polymorphisms of the CYP1A1 and glutathione S-transferase genes associated with susceptibility to lung cancer in relation to cigarette dose in a Japanese population. Cancer Res., 53: 2994-2999, 1993.
45. Heckbert, S. R., Weiss, N. S , Hornung, S K., Eaton, D. L., and Motulsky, A. G Glutathione S-transferase and epoxide hydrolase activity in human leukocytes in relation to risk of lung cancer and other smoking-related cancers. J. Natl. Cancer Inst, 84: 414-422, 1992
46. Hermanek, P., and Sobin, L. (eds), TNM Classification of Malignant Tumors. Berlin: Springer-Verlag, 131-146, 1987
47. Vineis, P , and Simonato, L. Proportion of lung and bladder cancers m males resulting from occupation: a systematic approach. Arch. Environ. Health, 46: 6-15, 1991.
48. Silverman, D T., Levin, L. I , Hoover, R. N., and Hartge, P. Occupational risks of bladder cancer in the United States. I. White men J. Natl Cancer Inst., 81 1472-1480, 1989.
49. Kunze, E., Chang-Claude, J., and Frentzel-Beyme, R. Life style and occupational risk factors for bladder cancer in Germany. Cancer (Phila.), 69: 1776-1790, 1992.
50. Roots, I., Drakoulis, N., Ploch, M , Heinemeyer, G , Loddenkemper, R , Minks, T , Nitz, M., Otte, F., and Koch, M. Debrisoquine hydroxylation phenotype, acetylation phenotype, and AB0 blood groups as genetic host factors of lung cancer risk. Klin Wochenschr , 66 (Suppl. 11): 87-97, 1988.
51. Chen, Z. R., Somogyi, A A., and Bochner, F. Simultaneous determination of dextromethorphan and three metabolites in plasma and urine using high-performance liquid chromatography with application to their disposition in man Ther. Drug Monit., 12: 97-104, 1990.
52. Skoda, R. C., Gonzalez, F J , Demierre, A., and Meyer, U. A. Two mutant alleles of the human cytochrome P-450db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs. Proc. Natl. Acad. Sci. USA, 85: 5240-5243, 1988.
53. Heim, M., and Meyer, U. A Genotyping of poor metabolizers of debrisoquine by allele-specific PCR amplification. Lancet. 336: 529-532, 1990.
54. Kimura, S , Umeno, M , Skoda, R C , Meyer, U. A , and Gonzalez, F J The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene Am J Hum. Genet., 45: 889-904, 1989.
55. Armstrong, M , Fairbrother, K., Idie, J. R , and Daly, A K. The cytochrome P450 CYP2D6 variant CYP2D6J and related polymorphisms in a European population. Pharmacogenetics, 4: 73-81, 1994.
56. Roots, I., Brockmöller, J., Drakoulis, N , and Loddenkemper, R Mutant genes of cytochrome, P-450IID6, glutathione S-transferase class μ, and arylamine N-acetyltransferase in lung cancer patients. Clin. Invest., 70: 307-319, 1992.
57. Daly, A. K , Brockmöller, J., Broly, F , Eichelbaum, M , Evans, W E., Gonzalez, F. J , Huang, J. D , Idle, J. R., Ingelman-Sundberg, M , Ishizaki, T , Jacqz-Aigrain, E., Meyer, U. A., Nebert, D., Steen, V , Wolf, C. R., and Zanger, U. M. Nomenclature for human CYP2D6 alleles. Pharmacogenetics, 6: 193-201, 1996.
58. Johansson, I., Lundqvist, E., Bertilsson, L., Dahl, M-L., Sjöqvist, F., and Ingelman-Sundberg M Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad. Sci USA, 90: 11825-11829, 1993.
59. Brockmöller, J., Rost, K. L., Gross, D., Schenkel, A., and Roots, I Phenotyping of CYP2C19 with enantiospecific HPLC-quantification of R- and S-mephenytoin and comparison with the intron 4/exon 5 G→A-splice site mutation. Pharmacogenetics, 5: 80-88, 1995.
60. Umeno, M., McBride, O. W , Yang, C. S., Gelboin, H V., and Gonzalez, F J. Human ethanol-inducible P450IIE1, complete gene sequence, promoter characterization, chromosome mapping, and cDNA-directed expression. Biochemistry, 27: 9006-9013, 1988.
61. McBride, O. W , Umeno, M., Gelboin, H. V., and Gonzalez, F. J. A TaqI polymorphism in the human P450IIE1 gene on chromosome 10 (CYP2E). Nucleic Acids Res., 15: 10071, 1987.
62. Schlesselman, J J. Case-control studies Design, Conduct, Analysis New York. Oxford University Press, 1982
63. Mantel, N., and Haenszel, W. Statistical aspects of the analysis of data from retrospective studies of disease J. Natl. Cancer Inst., 22: 719-748, 1959.
64. SAS Institute, Inc. SAS/STAT User's Guide, Release 6.03 Cary, NC SAS Institute, 1988
65. Breslow, N. E., and Day, N. E. Statistical Methods in Cancer Research. I. The Analysis of Case-Control Studies. IARC Scientific Publ. no 32. Lyon, France: IARC, 1980.
66. Dixon, W J. (ed.). BMDP Statistical Software Manual Berkeley: University of California Press, 1992.
67. Taubes, G. Epidemiology faces its limits (editorial) Science (Washington DC), 269: 164-169, 1995.
68. Lower, G M , Nilsson, T., Nelson, C. E., Wolf, H., Gamsky, T W., and Bryan, G. T. N-acetyltransferase phenotype and risk in urinary bladder cancer: approaches in molecular epidemiology. Preliminary results in Sweden and Denmark. Environ. Health Perspect., 29: 71-79, 1979.
69. Cartwright, R. A., Glasham, R. W , Rogers, H. J., Ahmad, R. A., Barham-Hall, D., Higgins, E., and Khan, M. A. Role of N-acetyltransferase phenotypes in bladder carcinogenesis: a pharmacogenetic epidemiological approach to bladder cancer Lancet, 2: 842-846, 1984.
70. Risch, A., Wallace, D. M A., Bathers, S., and Sim, E. Slow N-acetylation genotype is a susceptibility factor in occupational and smoking related bladder cancer. Hum Mol. Genet., 4: 231-236, 1995
71. Cascorbi, I., Brockmöller, J., Mrozikiewicz, P. M., Bauer, S , Loddenkemper, R., and Roots, I. Homozygous rapid arylamine N-acetyltransferase (NAT2) genotypes as susceptibility factor for lung cancer Cancer Res , 56 3961-3966, 1996.
72. Hein, D. W., Doll, M. A., Rustan, T. D., and Ferguson, R J. Metabolic activation of N-hydroxyarylamines and N-hydroxyarylamides by 16 recombinant human NAT2 allozymes. effects of 7 specific NAT2 nucleic acid substitutions. Cancer Res , 55: 3531-3536, 1995.
73. Kloth, M. T., Gee, R. L., Messing, E. M , and Swaminathan, S Expression of N-acetyltransferase (NAT) in cultured human uroepithelial cells. Carcinogenesis (Lond ), 15: 2781-2787, 1994.
74. Hayes, R. B., Bi, W., Rothman, N., Broly, F., Caporaso, N., Feng, P , You, X., Yin, S., Woosley, R. L , and Meyer, U. A. N-acetylation phenotype and genotype and risk of bladder cancer in benzidine-exposed workers. Carcinogenesis (Lond.), 14: 675-678, 1993.
75. Bell, D A , Badawi, A F., Lang, N. P., Ilett, K. F., Kadlubar, F. F , and Hirvonen, A. Polymorphism in the N-acetyltransferase 1 (NAT1) polyadenylation signal: association of NAT1<10 allele with higher N-acetylation activity in bladder and colon tissue. Cancer Res., 55: 5226-5229, 1995.
76. Hirvonen, A., Nylund, L., Kociba, P , Husgafvel-Pursianinen, K , and Vainio, H. Modulation of urinary mutagenicity by genetically determined carcinogen metabolism in smokers. Carcinogenesis (Lond.), 15: 813-815, 1994
77. Wiencke, J. K., Kelsey, K. T., Lamela, R. A., and Toscano, W. A. Human glutathione S-transferase deficiency as a marker of susceptibility to epoxide-induced cytogenetic damage. Cancer Res., 50: 1585-1590, 1990.
78. Shields, P G., Bowman, E. D., Harrington A M., Doan, V. T., and Weston, A Polycyclic aromatic hydrocarbon-DNA adducts in human lung and cancer susceptibility genes. Cancer Res., 53: 3486-3492, 1993.
79. McGlynn, K., Rosvold, E. A., Lustbader, E. D., Hu, Y., Clapper, M. L , Zhou, T , Wild, C. P , Xia, X-L , Baffoe-Bonnie, A., Ofori-Adjei, D., Chen, G-C , London, W. T , Shen, F-M , and Buetow, K. H. Susceptibility to hepatocellular carcinoma is associated with genetic variation in the enzymatic detoxification of aflatoxin B1. Proc. Natl Acad. Sci USA , 92: 2384-2387, 1995.
80. Grinberg-Funes, R. A., Singh, V. N., Perera, F. P , Bell, D A., Young, T. L., Dickey, C., Wang, L. W., and Santella, R. M. Polycyclic aromatic hydrocarbon. DNA adducts in smokers and their relationship to micronutrient levels and the glutathione-S-transferase M1 genotype. Carcinogenesis (Lond ), 15: 2449-2454, 1994
81. Vos, R M E, van Welie, R. T. H , Peters, W H. M., Evelo, C. T A., Boogaards, J J. P , Vermeulen, N. P. E., and van Bladeren, P. J. Genetic deficiency of human class μ glutathione S-transferase isoenzymes m relation to the urinary excretion of the mercapturic acids of Z- and E-1.3-dichloropropene Arch. Toxicol., 65: 95-99, 1991.
82. Shaw, G. L., Falk, R. T , Deslauriers, J , Frame, J N., Nesbitt, J C , Pass, H. I , Issaq, H. J., Hoover, R. N , and Tucker, M A Debrisoquine metabolism and lung cancer risk Cancer Epidemiol., Biomarkers & Prev., 4 41-48, 1995.
83. Landi, M T., Bertazzi, P. A., Shields, P G., Clark, G., Lucier, G W., Garte, S. J., Cosma, G , and Caporaso, N. E. Association between CYP1A1 genotype, mRNA expression and enzymatic activity in humans. Pharmacogenetics, 4: 242-246, 1994.